Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

BACKGROUND: We showed in a randomized double-blinded placebo-controlled clinical trial that octreotide long-acting repeatable depot.® (OctLAR(®)) for 12 months reduces kidney and liver growth in autosomal dominant polycystic kidney patients with severe polycystic liver disease (PLD) and liver growth...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hogan, Marie C., Masyuk, Tetyana V., Page, Linda, Holmes, David R., Li, Xujian, Bergstralh, Eric J., Irazabal, Maria V., Kim, Bohyun, King, Bernard F., Glockner, James F., LaRusso, Nicholas F., Torres, Vicente E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2012
Soggetti:
Clinical Science
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3433774/
https://ncbi.nlm.nih.gov/pubmed/22773240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfs152
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi